Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 291

1.

A systematic review on barriers hindering adequate cancer pain management and interventions to reduce them: a critical appraisal.

Oldenmenger WH, Sillevis Smitt PA, van Dooren S, Stoter G, van der Rijt CC.

Eur J Cancer. 2009 May;45(8):1370-80. doi: 10.1016/j.ejca.2009.01.007. Epub 2009 Feb 7. Review.

PMID:
19201599
2.

Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-alpha therapy.

Fekkes D, Van Gool AR, Bannink M, Sleijfer S, Kruit WH, van der Holt B, Eggermont AM, Hengeveld MW, Stoter G.

Amino Acids. 2009 Oct;37(4):703-8. doi: 10.1007/s00726-008-0191-x. Epub 2008 Oct 26.

3.

Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-alpha: course and relationship with psychiatric status.

Van Gool AR, Verkerk R, Fekkes D, Bannink M, Sleijfer S, Kruit WH, van der Holt B, Scharpé S, Eggermont AM, Stoter G, Hengeveld MW.

Psychiatry Clin Neurosci. 2008 Oct;62(5):597-602. doi: 10.1111/j.1440-1819.2008.01854.x.

4.

Plasma activity of prolyl endopeptidase in relation to psychopathology during immunotherapy with IFN-alpha in patients with renal cell carcinoma.

Van Gool AR, Verkerk R, Fekkes D, Sleijfer S, Bannink M, Kruit WH, van der Holt B, Scharpé S, Eggermont AM, Stoter G, Hengeveld MW.

J Interferon Cytokine Res. 2008 May;28(5):283-6. doi: 10.1089/jir.2007.0058.

PMID:
18547158
5.

Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated.

Bannink M, Kruit WH, Van Gool AR, Sleijfer S, van der Holt B, Eggermont AM, Stoter G, Hengeveld MW.

Psychosomatics. 2008 Jan-Feb;49(1):56-63. doi: 10.1176/appi.psy.49.1.56.

PMID:
18212177
6.

Serum proteomic patterns for ovarian cancer monitoring.

Helleman J, van der Vlies D, Jansen MP, Luider TM, van der Burg ME, Stoter G, Berns EM.

Int J Gynecol Cancer. 2008 Sep-Oct;18(5):985-95. Epub 2007 Nov 20.

PMID:
18028381
7.

Bleomycin and scuba diving: where is the harm?

de Wit R, Sleijfer S, Kaye SB, Horwich A, Mead B, Sleijfer DT, Stoter G.

Lancet Oncol. 2007 Nov;8(11):954-5. No abstract available.

PMID:
17976605
8.

Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effects.

Bannink M, Fekkes D, Van Gool AR, Kruit WH, Sleijfer S, van der Holt B, Eggermont AM, Stoter G, Hengeveld MW.

Neuropsychobiology. 2007;55(3-4):225-31. Epub 2007 Sep 17.

PMID:
17873497
9.

Analgesic adherence measurement in cancer patients: comparison between electronic monitoring and diary.

Oldenmenger WH, Echteld MA, de Wit R, Sillevis Smitt PA, Stronks DL, Stoter G, van der Rijt CC.

J Pain Symptom Manage. 2007 Dec;34(6):639-47. Epub 2007 Aug 20.

PMID:
17703909
10.

Mismatch repair and treatment resistance in ovarian cancer.

Helleman J, van Staveren IL, Dinjens WN, van Kuijk PF, Ritstier K, Ewing PC, van der Burg ME, Stoter G, Berns EM.

BMC Cancer. 2006 Jul 31;6:201.

11.

Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter.

Helleman J, Burger H, Hamelers IH, Boersma AW, de Kroon AI, Stoter G, Nooter K.

Cancer Biol Ther. 2006 Aug;5(8):943-9. Epub 2006 Aug 2.

PMID:
16775422
12.

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, Gratama JW, Stoter G, Oosterwijk E.

J Clin Oncol. 2006 May 1;24(13):e20-2. No abstract available.

PMID:
16648493
13.

Late-onset retinoblastoma in a well-functioning fellow eye.

de Jong PT, Mooy CM, Stoter G, Eijkenboom WM, Luyten GP.

Ophthalmology. 2006 Jun;113(6):1040-4. Epub 2006 May 2.

PMID:
16631255
14.

Influence of pegylated interferon-alpha therapy on plasma levels of citrulline and arginine in melanoma patients.

Fekkes D, Bannink M, Kruit WH, Van Gool AR, Mulder PG, Sleijfer S, Eggermont AM, Stoter G.

Amino Acids. 2007 Jan;32(1):121-6. Epub 2006 Apr 20.

PMID:
16622596
15.

Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values.

Loos WJ, de Jongh FE, Sparreboom A, de Wit R, van Boven-van Zomeren DM, Stoter G, Nooter K, Verweij J.

J Clin Oncol. 2006 Apr 1;24(10):1499-506.

PMID:
16574999
16.
17.

What is the role of dose-dense therapy?

van der Burg ME, van der Gaast A, Vergote I, Burger CW, van Doorn HC, de Wit R, Stoter G, Verweij J.

Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:233-40. Review.

18.

Side effects of interferon-alpha therapy.

Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G.

Pharm World Sci. 2005 Dec;27(6):423-31.

PMID:
16341948
19.

Molecular profiling of platinum resistant ovarian cancer.

Helleman J, Jansen MP, Span PN, van Staveren IL, Massuger LF, Meijer-van Gelder ME, Sweep FC, Ewing PC, van der Burg ME, Stoter G, Nooter K, Berns EM.

Int J Cancer. 2006 Apr 15;118(8):1963-71. Erratum in: Int J Cancer. 2006 Aug 1;119(3):726.

20.

Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?

Sleijfer S, Stoter G.

Nat Clin Pract Oncol. 2005 Feb;2(2):70-1. No abstract available.

PMID:
16264874
21.

The potential of statins as part of anti-cancer treatment.

Sleijfer S, van der Gaast A, Planting AS, Stoter G, Verweij J.

Eur J Cancer. 2005 Mar;41(4):516-22. Epub 2005 Jan 11. Review.

PMID:
15737555
22.

Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant.

Portielje JE, Kruit WH, Eerenberg AJ, Schuler M, Sparreboom A, Lamers CH, Gratama JW, Stoter G, Huber C, Hack CE.

Cancer Immunol Immunother. 2005 Jan;54(1):37-43.

PMID:
15693137
23.

Platelet MAO activity during treatment with pegylated interferon-alfa in melanoma patients.

Bannink M, Kruit WH, Van Gool AR, Mulder PG, Sleijfer S, Eggermont AM, Stoter G, Fekkes D.

Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jan;29(1):109-14. Epub 2004 Nov 18.

PMID:
15610952
24.

Thalidomide in solid tumours: the resurrection of an old drug.

Sleijfer S, Kruit WH, Stoter G.

Eur J Cancer. 2004 Nov;40(16):2377-82. Review.

PMID:
15519508
25.

Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes.

Lamers CH, Sleijfer S, Willemsen RA, Debets R, Kruit WH, Gratama JW, Stoter G.

J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):134-40. Review.

PMID:
15471217
27.

Serum activity of prolyl endopeptidase, but not of dipeptidyl peptidase IV, is decreased by immunotherapy with IFN-alpha in high-risk melanoma patients.

Van Gool AR, Van Ojik HH, Kruit WH, Mulder PG, Fekkes D, Bannink M, Scharpé S, Stoter G, Eggermont AM, Maes M, Verkerk R.

J Interferon Cytokine Res. 2004 Jul;24(7):411-5.

PMID:
15296652
28.

Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1.

Schenk PW, Stoop H, Bokemeyer C, Mayer F, Stoter G, Oosterhuis JW, Wiemer E, Looijenga LH, Nooter K.

Neoplasia. 2004 Jul-Aug;6(4):297-301.

29.

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.

Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, Nooter K.

Blood. 2004 Nov 1;104(9):2940-2. Epub 2004 Jul 13.

PMID:
15251980
30.

Pegylated interferon-alpha2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations.

Van Gool AR, van Ojik HH, Kruit WH, Bannink M, Mulder PG, Eggermont AM, Stoter G, Fekkes D.

Anticancer Drugs. 2004 Jul;15(6):587-91.

PMID:
15205601
31.

A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer.

Polee MB, Sparreboom A, Eskens FA, Hoekstra R, van de Schaaf J, Verweij J, Stoter G, van der Gaast A.

Clin Cancer Res. 2004 Mar 15;10(6):1928-34.

32.

Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors.

Vantomme V, Dantinne C, Amrani N, Permanne P, Gheysen D, Bruck C, Stoter G, Britten CM, Keilholz U, Lamers CH, Marchand M, Delire M, Guéguen M.

J Immunother. 2004 Mar-Apr;27(2):124-35.

PMID:
14770084
33.

Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial.

ten Tije AJ, Smorenburg CH, Seynaeve C, Sparreboom A, Schothorst KL, Kerkhofs LG, van Reisen LG, Stoter G, Bontenbal M, Verweij J.

Eur J Cancer. 2004 Feb;40(3):352-7.

PMID:
14746852
34.

Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy.

Polee MB, Hop WC, Kok TC, Eskens FA, van der Burg ME, Splinter TA, Siersema PD, Tilanus HW, Stoter G, van der Gaast A.

Br J Cancer. 2003 Dec 1;89(11):2045-50.

35.

Functional cloning of drug resistance genes from retroviral cDNA libraries.

Bosma PT, van Eert SJ, Jaspers NG, Stoter G, Nooter K.

Biochem Biophys Res Commun. 2003 Sep 26;309(3):605-11.

PMID:
12963033
36.

Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.

Ten Tije AJ, Verweij J, Sparreboom A, Van Der Gaast A, Fowst C, Fiorentini F, Tursi J, Antonellini A, Mantel M, Hartman CM, Stoter G, Planting AS, De Jonge MJ.

Clin Cancer Res. 2003 Aug 1;9(8):2957-64.

37.

Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus.

Polee MB, Tilanus HW, Eskens FA, Hoekstra R, Van der Burg ME, Siersema PD, Stoter G, Van der Gaast A.

Ann Oncol. 2003 Aug;14(8):1253-7.

PMID:
12881388
38.

Anticancer drug resistance induced by disruption of the Saccharomyces cerevisiae NPR2 gene: a novel component involved in cisplatin- and doxorubicin-provoked cell kill.

Schenk PW, Brok M, Boersma AW, Brandsma JA, Den Dulk H, Burger H, Stoter G, Brouwer J, Nooter K.

Mol Pharmacol. 2003 Aug;64(2):259-68.

PMID:
12869630
39.

Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients.

de Jongh FE, van Veen RN, Veltman SJ, de Wit R, van der Burg ME, van den Bent MJ, Planting AS, Graveland WJ, Stoter G, Verweij J.

Br J Cancer. 2003 Apr 22;88(8):1199-206.

40.

Neuropsychiatric side effects of interferon-alfa therapy.

Van Gool AR, Kruit WH, Engels FK, Stoter G, Bannink M, Eggermont AM.

Pharm World Sci. 2003 Feb;25(1):11-20. Review.

PMID:
12661471
41.

Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens.

Burger H, den Bakker MA, Stoter G, Verweij J, Nooter K.

Eur J Cancer. 2003 Apr;39(6):793-9.

PMID:
12651205
42.

IL-12: a promising adjuvant for cancer vaccination.

Portielje JE, Gratama JW, van Ojik HH, Stoter G, Kruit WH.

Cancer Immunol Immunother. 2003 Mar;52(3):133-44. Epub 2003 Feb 12. Review.

PMID:
12649742
43.

Paraneoplastic ophthalmoplegia and subacute motor axonal neuropathy associated with anti-GQ1b antibodies in a patient with malignant melanoma.

Kloos L, Sillevis Smitt P, Ang CW, Kruit W, Stoter G.

J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):507-9.

44.

Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis.

Loos WJ, Gelderblom H, Verweij J, van Boven-van Zomeren DM, Nooter K, Stoter G, Sparreboom A.

Anticancer Drugs. 2003 Mar;14(3):227-32.

PMID:
12634617
46.
47.

Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel.

Smorenburg CH, Sparreboom A, Bontenbal M, Stoter G, Nooter K, Verweij J.

J Clin Oncol. 2003 Jan 15;21(2):197-202.

PMID:
12525510
48.

Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report.

Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, Håkansson L, van Baren N, Humblet Y, Mulders P, Avril MF, Eggermont AM, Scheibenbogen C, Uiters J, Wanders J, Delire M, Boon T, Stoter G.

Eur J Cancer. 2003 Jan;39(1):70-7.

PMID:
12504661
49.

Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer.

de Jongh FE, de Wit R, Verweij J, Sparreboom A, van den Bent MJ, Stoter G, van der Burg ME.

Eur J Cancer. 2002 Oct;38(15):2005-13.

PMID:
12376205
50.

Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel.

Loos WJ, Szebeni J, ten Tije AJ, Verweij J, van Zomeren DM, Chung KN, Nooter K, Stoter G, Sparreboom A.

Anticancer Drugs. 2002 Aug;13(7):767-75.

PMID:
12187334

Supplemental Content

Loading ...
Support Center